Anavex Secures cGMP Manufacture for ANAVEX Trials

Anavex Life Sciences Corp. has secured cGMP manufacture of ANAVEX 2-73 for its clinical trial supplies. Further details were not disclosed.
 
“We are delighted to have the active drug product (API) manufactured and available for our Phase IIa trial,” said Christopher U. Missling, PhD, president and chief executive officer of Anavex. “We look forward to initiating clinical trials with ANAVEX PLUS for the treatment of Alzheimer’s disease, which remains on track to commence in 2014 with data from the first part of the trial expected to be reported in mid 2015.”